Partial Inhibition of Platelet Thromboxane A2 Synthesis by Aspirin Is Associated With Myonecrosis in Patients With ST-Segment Elevation Myocardial Infarction

This publication has 27 references indexed in Scilit:

• Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
  Chest, 2004
• Genetic and Acquired Determinants of Individual Variability of Response to Antiplatelet Drugs
  Circulation, 2003
• A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease
  Journal of the American College of Cardiology, 2003
• Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events
  Circulation, 2002
• Common variations in platelet glycoproteins: pharmacogenomic implications
  Pharmacogenomics, 2001
• Profile and prevalence of aspirin resistance in patients with cardiovascular disease
  The American Journal of Cardiology, 2001
• Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study
  Journal of the Neurological Sciences, 1999
• Erythrocyte Promotion of Platelet Reactivity Decreases the Effectiveness of Aspirin as an Antithrombotic Therapeutic Modality
  Circulation, 1998
• Development of aspirin resistance in persons with previous ischemic stroke.
  Stroke, 1994
• Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients
  Thrombosis Research, 1993